NASDAQ:FPRX Five Prime Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Five Prime Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.49 +0.29 (+6.90 %) (As of 09/25/2020 03:23 PM ET) Add Compare Share Today's Range$4.27Now: $4.49▼$4.6150-Day Range$3.81MA: $4.46▼$6.1252-Week Range$1.75Now: $4.49▼$7.34Volume25,256 shsAverage Volume398,890 shsMarket Capitalization$164.46 millionP/E RatioN/ADividend YieldN/ABeta2.68 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; a collaboration agreement with Roche; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingFive Prime Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Five Prime Therapeutics has a forecasted upside of 124.7% from its current price of $4.45.Amount of Analyst CoverageFive Prime Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesFive Prime Therapeutics has received 300 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFive Prime Therapeutics has received 241 “underperform” votes. (Add your “underperform” vote.)Community SentimentFive Prime Therapeutics has received 55.45% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote “Outperform” if you believe FPRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FPRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFive Prime Therapeutics does not currently pay a dividend.Dividend GrowthFive Prime Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Five Prime Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $122.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Five Prime Therapeutics is held by insiders.Percentage Held by Institutions73.46% of the stock of Five Prime Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Five Prime Therapeutics are expected to grow in the coming year, from ($2.40) to ($1.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Five Prime Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Five Prime Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFive Prime Therapeutics has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.14 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FPRX Previous Symbol CUSIPN/A CIK1175505 Webwww.fiveprime.com Phone415-365-5600Debt Debt-to-Equity RatioN/A Current Ratio6.72 Quick Ratio6.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$14.87 million Price / Sales11.06 Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book1.09Profitability EPS (Most Recent Fiscal Year)($3.92) Net Income$-137,200,000.00 Net Margins-579.41% Return on Equity-71.64% Return on Assets-47.98%Miscellaneous Employees209 Outstanding Shares36,628,000Market Cap$164.46 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $4.49 +0.29 (+6.90 %) (As of 09/25/2020 03:23 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive FPRX News and Ratings via Email Sign-up to receive the latest news and ratings for FPRX and its competitors with MarketBeat's FREE daily newsletter. Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions How has Five Prime Therapeutics' stock been impacted by COVID-19? Five Prime Therapeutics' stock was trading at $2.93 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FPRX shares have increased by 53.2% and is now trading at $4.49. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Five Prime Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Five Prime Therapeutics. When is Five Prime Therapeutics' next earnings date? Five Prime Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Five Prime Therapeutics. How were Five Prime Therapeutics' earnings last quarter? Five Prime Therapeutics Inc (NASDAQ:FPRX) announced its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.48) EPS for the quarter, topping analysts' consensus estimates of ($0.70) by $0.22. The biotechnology company earned $3.42 million during the quarter, compared to the consensus estimate of $4.43 million. Five Prime Therapeutics had a negative return on equity of 71.64% and a negative net margin of 579.41%. View Five Prime Therapeutics' earnings history. What price target have analysts set for FPRX? 4 equities research analysts have issued 12 month price targets for Five Prime Therapeutics' stock. Their forecasts range from $9.00 to $11.00. On average, they anticipate Five Prime Therapeutics' share price to reach $10.00 in the next year. This suggests a possible upside of 122.7% from the stock's current price. View analysts' price targets for Five Prime Therapeutics. Who are some of Five Prime Therapeutics' key competitors? Some companies that are related to Five Prime Therapeutics include DiaMedica Therapeutics (DMCAF), Collegium Pharmaceutical (COLL), ImmunoGen (IMGN), Northwest Biotherapeutics (NWBO), Basilea Pharmaceutica (BPMUF), ORIC Pharmaceuticals (ORIC), Eagle Pharmaceuticals (EGRX), Zafgen (ZFGN), Legend Biotech (CALT), Omeros (OMER), XBiotech (XBIT), Syndax Pharmaceuticals (SNDX), Axovant Sciences (AXON), Geron (GERN) and Flexion Therapeutics (FLXN). View all competitors. What other stocks do shareholders of Five Prime Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Five Prime Therapeutics investors own include Gilead Sciences (GILD), Opko Health (OPK), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Mallinckrodt (MNK), Pfizer (PFE), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN) and Novavax (NVAX). Who are Five Prime Therapeutics' key executives? Five Prime Therapeutics' management team includes the following people: Mr. Aron Marc Knickerbocker, Pres, CEO & Director (Age 50)Mr. Francis W. Sarena, Chief Strategy Officer & Sec. (Age 48)Dr. Helen Louise Collins, Sr. VP & Chief Medical Officer (Age 56)Dr. Peder K. Jensen, Advisor & Director (Age 64)Mr. David V. Smith, Exec. VP & CFO What is Five Prime Therapeutics' stock symbol? Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX." Who are Five Prime Therapeutics' major shareholders? Five Prime Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (21.81%), Assenagon Asset Management S.A. (1.77%), Two Sigma Advisers LP (1.11%), AQR Capital Management LLC (0.96%), Platinum Investment Management Ltd. (0.89%) and First Republic Investment Management Inc. (0.75%). Company insiders that own Five Prime Therapeutics stock include Andrew T Feldstein, Bvf Partners L P/Il, Franklin M Berger and Value Fund L P Biotechnology. View institutional ownership trends for Five Prime Therapeutics. Which institutional investors are selling Five Prime Therapeutics stock? FPRX stock was sold by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, AQR Capital Management LLC, Tudor Investment Corp Et Al, PDT Partners LLC, Nuveen Asset Management LLC, Man Group plc, Bank of New York Mellon Corp, and New York State Common Retirement Fund. View insider buying and selling activity for Five Prime Therapeutics. Which institutional investors are buying Five Prime Therapeutics stock? FPRX stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., First Republic Investment Management Inc., Jacobs Levy Equity Management Inc., BVF Inc. IL, Goldman Sachs Group Inc., Platinum Investment Management Ltd., SG Americas Securities LLC, and Bridgeway Capital Management Inc.. Company insiders that have bought Five Prime Therapeutics stock in the last two years include Andrew T Feldstein, Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Five Prime Therapeutics. How do I buy shares of Five Prime Therapeutics? Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Five Prime Therapeutics' stock price today? One share of FPRX stock can currently be purchased for approximately $4.49. How big of a company is Five Prime Therapeutics? Five Prime Therapeutics has a market capitalization of $164.46 million and generates $14.87 million in revenue each year. The biotechnology company earns $-137,200,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Five Prime Therapeutics employs 209 workers across the globe. What is Five Prime Therapeutics' official website? The official website for Five Prime Therapeutics is www.fiveprime.com. How can I contact Five Prime Therapeutics? Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
